Compare SQNS & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SQNS | IXHL |
|---|---|---|
| Founded | 2003 | 2001 |
| Country | France | Australia |
| Employees | N/A | N/A |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.9M | 39.0M |
| IPO Year | 2011 | 2024 |
| Metric | SQNS | IXHL |
|---|---|---|
| Price | $2.74 | $3.25 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 35.4K | ★ 75.0K |
| Earning Date | 11-03-2026 | 09-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000.00 |
| Revenue This Year | $33.92 | N/A |
| Revenue Next Year | $66.21 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.38 | $0.16 |
| 52 Week High | $10.19 | $6.39 |
| Indicator | SQNS | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 41.09 | 44.93 |
| Support Level | $2.72 | $3.10 |
| Resistance Level | $3.19 | $3.87 |
| Average True Range (ATR) | 0.17 | 0.20 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 1.20 | 14.08 |
Sequans Communications SA is a fabless semiconductor company specializing in wireless 4G and 5G cellular technologies for the Internet of Things (IoT). Sequans' engineers design and develop, secure, and energy-efficient semiconductor solutions that enable the next generation of AI-connected applications, including smart energy metering, industrial automation, smart mobility and logistics, secure payments, e-health, and smart home solutions. The Company offers a comprehensive portfolio of wireless connectivity solutions, including radio frequency (RF) transceivers, integrated circuits (ICs) for baseband processing, as well as modules, software, & protocol stacks. The Company has one operating segment, which is the design & marketing of semiconductor components for cellular wireless systems.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.